

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address

Jolt Health Inc. (the “Company”)
1780-355 Burrard Street
Vancouver, BC
V6C 2C8

Item 2. Date of Material Change

July 17, 2023

Item 3. News Release

The news release describing the material change was disseminated on July 19, 2023 through Globe Newswire and filed on SEDAR.

Item 4. Summary of Material Change

The Company announced it has closed its previously announced non-brokered private placement. The Company accepted subscriptions for 6,984,265 units at a price of \$0.0143 per unit (the “Units”) for gross proceeds of \$99,875.

One insider of the Company subscribed for an aggregate of 1,400,000 units of the Company. The Company has relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(a) of MI 61-101 in respect of such insider participation.

The Company paid \$1,251.25 in cash and issued 87,500 finder’s warrants to a qualified finder. Securities issued are subject to trading restrictions until November 18, 2023.

Item 5. Full Description of Material Change

5.1 *Full Description of Material Change*

The Company announced it has closed its previously announced non-brokered private placement. The Company accepted subscriptions for 6,984,265 units at a price of \$0.0143 per unit (the “Units”) for gross proceeds of \$99,875.

One insider of the Company subscribed for an aggregate of 1,400,000 units of the Company. The Company has relied on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(a) of MI 61-101 in respect of such insider participation.

Pursuant to the terms of the Financing, each Unit consists of one common share in the equity of the Company and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.05 per share for a period of two (2) years from the closing of the Financing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at \$0.15 or more for 10 consecutive days.

The Company paid \$1,251.25 in cash and issued 87,500 finder's warrants to a qualified finder. Securities issued are subject to trading restrictions until November 18, 2023.

Proceeds will be used for working capital and to review possible acquisitions.

5.2 *Disclosure for Restructuring Transactions*

Not applicable.

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

No information has been omitted in respect of this material change.

Item 8. Executive Officer

The following executive officer of the Company is knowledgeable about the material change disclosed in this report and may be contacted as follows:

Gerald Tritt, President and CEO
Telephone: 778 717-3489

Item 9. Date of Report

July 19, 2023